The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Bishop, Michael
One or more keywords matched the following items that are connected to Bishop, Michael
Item TypeName
Concept Receptors, Antigen, T-Cell, alpha-beta
Concept Receptors, Antigen, T-Cell
Academic Article Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Academic Article Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.
Academic Article Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
Academic Article Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
Academic Article Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
Academic Article Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.
Academic Article Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Academic Article Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Academic Article Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
Academic Article Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Academic Article Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Academic Article Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Academic Article Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.
Academic Article Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
Search Criteria
  • Receptors Antigen B Cell